What is Xarelto?
Xarelto is a prescription anti-coagulant that was approved by the Food and Drug Administration (FDA) and released onto the United States market in 2011. Xarelto’s active ingredient is rivaroxaban and belongs to a class of blood thinners known as Xa Inhibitors. Xa inhibitors are different from other blood thinners because they work to prevent blood clots by blocking a crucial chemical in the blood, Thrombin, which is responsible for making blood clot.
Why Should I Be Concerned About Xarelto?
Xarelto has many doctors and research scientists concerned because there is no available antidote for the drug. Other commonly prescribed blood thinners, such as warfarin, all have corresponding antidotes that can be administered by doctors in the event of a medical emergency. If a patient is on Xarelto and experiences an internal bleeding emergency, there is no antidote that can be prescribed to them to counteract the effects of Xarelto and stop the internal bleeding.
Xarelto Studies and Warnings
Several studies have documented the negative effects of Xarelto. In January of 2015, Baylor College of Medicine in Texas performed a study funded by Bayer Healthcare and Janssen that asserted that there was a risk of serious internal bleeding associated with Xarelto usage. Researchers analyzed the health of 27,467 of the patients who were taking Xarelto (Rivaroxaban) between January 2013 and March 2014 and found that out of the patients studied, 478 individuals suffered from a major bleeding event and 14 individuals taking Xarelto died from the internal bleeding.
Doctors in residence at Erasmus MC University Medical Center in Rotterdam, The Netherlands studied various blood thinners in the same class as Xarelto, including Xarelto iteself and Pradaxa, to compare the risk of gastrointestinal bleeds while taking these medications as opposed to the standard blood thinners such as Warfarin. In Xarelto’s case, doctors found that usage carried an increased risk of internal bleeding almost 1.5 times higher than the risk Warfarin carried. These doctors were concerned about the fact that drugs in the Xa inhibitor class, including Xarelto, lacked an antidote.
To this date Xarelto has not been recalled by the FDA, but they have issued several of their own warnings in regards to the medication. One of the warnings issued in early 2014 advised patients and doctors of medications that could have dangerous, unintended interactions if taken with Xarelto. The following medications should never be prescribed with Xarelto
Itraconazole – Sporanox and Onmel
lopinavir – Kaletra
Ritonavir – Norvir
Indinavir – Crixivan
Conivaptan – Vaprisol
Carbamazepine – Tegretol, Tegretol-XR, Equetro, Carbatrol, Epitol, and Teril
Phenytoin – Dilantin
Rifampin – Rifater, Rifamate, Rimactane, and Rifadin
St. John’s wort – Hypericum Perforatum
Xarelto Injuries in South Dakota
Using data available to us, our team has been able to estimate the number of Xarelto injuries that have occurred in South Dakota. By comparing the number of Xarelto prescriptions written in the United States, to the populations of the United States, South Dakota, and South Dakota’s top five most populated cities, we are able to estimate the number of people who may have been injured for Xarelto since its release onto the U.S. market.
At the time of the 2010 U.S. Census, the population of South Dakota was 814,180. We estimate that there have been 29,007 residents across the state of South Dakota who may have experienced internal bleeding due to Xarelto usage. We have broken down the data by South Dakota’s top five most populous cities which can be seen below:
Populations of South Dakota’s Top Five Largest Cities
- Sioux Falls – 153,888
- Rapid City – 67,956
- Aberdeen – 26,091
- Brookings – 22056
- Watertown – 21482
- Sioux Falls – 93
- Rapid City – 41
- Aberdeen – 15
- Brookings – 13
- Watertown – 13
Legal Action Against Xarelto
If you believe that you or a loved one are part of the many who have been injured by Xarelto in South Dakota, you are not alone. Our Xarelto lawyers are here to help you seek justice and compensation.
The lawyers at Osborne & Associates have an excellent track record in regards to taking on large pharmaceutical companies. We take our cases seriously and our trial lawyers will fight aggressively for your justice. Over the past two years our firm has recovered over six billion dollars of compensation for our clients.
Our lawyers are licensed to practice law in Pennsylvania, New Jersey, Washington D.C. and Massachusetts. Even though we are only licensed in these locations, through our work on Xarelto litigation we have developed a network of excellent working relationships with lawyers in every state in the country who are able to handle Xarelto litigation. We will happily work with you to refer you to a lawyer in your home state if you wish to keep your case local. Contact us for a free case evaluation and consultation and we will help you get started on the path to justice.